Cargando…

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2

Detalles Bibliográficos
Autores principales:	Kaufman, Howard L, Aung, Sandra, Morse, Michael, Wong, Michael, Lowder, James, Daniels, Gregory, McDermott, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288765/ http://dx.doi.org/10.1186/2051-1426-2-S3-P88

Ejemplares similares

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
por: Kaufman, Howard L., et al.
Publicado: (2014)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
por: Wong, Michael K, et al.
Publicado: (2014)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
por: Chu, Melinda B., et al.
Publicado: (2013)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

Effects of Hd2 in the presence of the photoperiod-insensitive functional allele of Hd1 in rice
por: Zhang, Zhen-Hua, et al.
Publicado: (2016)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

Understanding HD Psychosis: An Analysis from the ENROLL-HD Database
por: Jaini, Ashwin, et al.
Publicado: (2020)

Reactions of H(2), HD, and D(2) with H(2)(+), HD(+), and D(2)(+): Product-Channel Branching Ratios and Simple Models
por: Merkt, Frédéric, et al.
Publicado: (2022)

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
por: Erbe, Amy K, et al.
Publicado: (2015)

Arabidopsis histone deacetylase HD2A and HD2B regulate seed dormancy by repressing DELAY OF GERMINATION 1
por: Han, Yongtao, et al.
Publicado: (2023)

HD2A and HD2C co-regulate drought stress response by modulating stomatal closure and root growth in Arabidopsis
por: Tahir, Muhammad Sufyan, et al.
Publicado: (2022)

Nutri-Calc HD
por: Mayne, Susan Taylor
Publicado: (1990)

Cloud Results HD
por: Noemi Caraban, et al.
Publicado: (2016)

CERN HD Stockshots
Publicado: (2005)

Digital Video and HD
por: Poynton, Charles
Publicado: (2003)

Reduced expression of dopamine D2 receptors on astrocytes in R6/1 HD mice and HD post-mortem tissue
por: Harris, Kate L., et al.
Publicado: (2022)

Disease Burden of Huntington’s Disease (HD) on People Living with HD and Care Partners in Canada
por: Shaw, Eileen, et al.
Publicado: (2022)

Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation
por: Seredenina, Tamara, et al.
Publicado: (2011)

Using Kindle Fire HD
por: Wilson, Kevin
Publicado: (2014)

My Kindle Fire HD
por: Cheshire, Jim, et al.
Publicado: (2013)

NOOK HD: the missing manual
por: Gralla, Preston
Publicado: (2013)

CERN General HD Stockshots
por: CERN audiovisual service, et al.
Publicado: (2008)

Final Cut Express HD
por: Weynand, Diana
Publicado: (2006)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance
por: Keogh, Ruth, et al.
Publicado: (2016)

A second HD mating type sublocus of Flammulina velutipes is at least di-allelic and active: new primers for identification of HD-a and HD-b subloci
por: Wang, Wei, et al.
Publicado: (2019)

IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model
por: Zhang, Cuiping, et al.
Publicado: (2021)

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
por: Chow, Shien, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j22hv63rr0fk0ai6lrb2q4e4k1